'김갑성' 기자의 전체기사
-
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercep…
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions INCHEON, South Korea, Oct. 10, 2025 -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
- 김갑성 기자
- 2025-10-10 06:56
-
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 As…
[ 메디채널 김갑성 기자 ] New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 10, 2025 -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal biomarker in Alzheimer's disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex s
- 김갑성 기자
- 2025-10-10 05:23
-
POMDOCTOR LIMITED Announces Closing of Initial Public Offerin…
GUANGZHOU, China, Oct. 10, 2025 -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs began trading on Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM." The Co
- 김갑성 기자
- 2025-10-10 04:05
-
Lifespan-Backed Algen Biotechnologies Partners with Astra…
NORWALK, Conn., Oct. 9, 2025 -- Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology. The partnership will combine Algen's cutting-edge functional genomics and machine learning platform with AstraZeneca's deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of n
- 김갑성 기자
- 2025-10-09 23:09
-
Kimberly-Clark Launches Enhanced Global Partnerships to…
DALLAS, Oct. 9, 2025 -- Kimberly-Clark Corporation (NASDAQ: KMB) is deepening its commitment to advancing essential care for women and girls through four enhanced strategic, charitable partnerships. Through new programs with Baby2Baby, Plan International, Project HOPE, and UNICEF, Kimberly-Clark aims to expand access to life-changing care in Brazil, Peru, China, India, Indonesia, Vietnam, and the United States. Taken together, these partnerships will work to improve the lives of an estimated 24 million women and girls over the next three years. Experience the full interactive
- 김갑성 기자
- 2025-10-09 21:05
-
킴벌리클라크, 전 세계 2400만 여성과 소녀를 위한 필수 돌봄 강화 글로벌 파트너십 발표
댈러스, 2025년 10월 9일 -- 킴벌리클라크 코퍼레이션(Kimberly-Clark Corporation)(나스닥: KMB)이 여성과 소녀를 위한 필수 돌봄을 발전시키기 위한 노력을 강화하기 위해 네 가지 강화된 전략적 자선 파트너십을 체결했다. 킴벌리클라크는 베이비투베이비(Baby2Baby), 플랜 인터내셔널(Plan International), 프로젝트 HOPE(Project HOPE), 유니세프(UNICEF)와의 이 새로운 프로그램을 통해 브라질, 페루, 중국, 인도, 인도네시아, 베트남, 미국에서 삶의 변화를 가져올 수 있는 돌봄에 대한 접근성을 확대할 계획이다. 이번 파트너십은 향후 3년간 약 2400만 명의 여성과 소녀들의 삶을 개선하는 데 기여할 것으로 기대된다. 전체 인터랙티브 멀티채널 뉴스 보도는 여기서 확인할 수 있다. https://www.multivu.com/kimberly-clark/9238951-en-kimberly-clark-global-partnerships-women-and-girls 이번 발표는 킴벌리클라크 재단(Kimberly-Clark Foundation)이 최근 전략적 초점을
- 김갑성 기자
- 2025-10-09 21:05
-
LuX-Valve Plus Approved for Hong Kong-Macao Medicine a…
BEIJING, Oct. 9, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, recently announced that LuX-Valve Plus transjugular tricuspid valve replacement system, the product of its subsidiary Jenscare Scientific (Netherlands) B.V., has been officially approved to be included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect, enabling commercial clinical application in designated medical institutions in mainland of
- 김갑성 기자
- 2025-10-09 21:00
-
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets…
[ 메디채널 김갑성 기자 ] The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperative setting The ASTRUM-006 study demonstrated a significant improvement in event-free survival (EFS) and achieved a more than threefold higher pathological complete response (pCR) rate compared with the control arm, unlocking the potential for a cure SHANGHAI, Oct. 9, 2025 -- Sha
- 김갑성 기자
- 2025-10-09 20:50
-
Field Medical First-in-Human 6-Month Data Selected for Late-B…
Three sessions feature new outcomes, a live case, and preclinical research with the FieldForce™ Ablation System. CARDIFF-BY-THE-SEA, Calif., and PHILADELPHIA, Oct. 9, 2025 -- Field Medical, Inc., a leader in pulsed field ablation (PFA) technology for ventricular tachycardia (VT), today announced its participation at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium), taking place Oct. 10 –11 in Philadelphia. Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablatio
- 김갑성 기자
- 2025-10-09 20:33
-
Samsung Biologics Introduces Optimized Manufacturing Fra…
ExellenS TM applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed ExellenS TM combines the company's commitment to operational excellence with its core manufacturing competencies, guided by standardization, simplification, and scalability ExellenS TM delivers faster tech transfers, rapid approvals, predictable outcomes, and global flexibility for clients INCHEON, South Korea, Oct. 9, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled Exe
- 김갑성 기자
- 2025-10-09 19:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분